Key result
CYP2C9 variant alleles are linked to lower weekly warfarin dose requirements than wild type.
Why the study?
The influence of CYP2C9 gene polymorphisms on warfarin dose requirements after heart valve replacement was investigated.
Observational (n=74)
OBJECTIVE: The aim of the present study was to investigate the role of CYP2C9 gene polymorphisms after heart valve replacement in a group of patients on warfarin therapy. MATERIALS AND METHODS: The study population consisted of 74 patients with heart valve replacement. Peripheral blood was collected into evacuated tubes containing EDTA, and DNA was extracted from circulating leukocytes by using a high pure PCR template preparation kit. CYP2C9*2, CYP2C9*3 alleles were detected by using real-time PCR. RESULTS: The patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes were taking 28.21 and 24.47 mg, respectively, as mean weekly warfarin dose, whereas patients with CYP2C9*1/*1 genotype were taking 33.90 mg. CONCLUSION: The data show that patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes needed a lower maintenance dose of warfarin than patients with CYP2C9*1/*1 wild-type genotype.
No takes yet. Share an insight, caveat, or question.
Tamer et al. (2008) conducted an observational in Heart valve replacement requiring anticoagulant therapy (n=74). CYP2C9 gene polymorphisms (CYP2C9*1/*3 and CYP2C9*2/*3 genotypes) vs. CYP2C9*1/*1 wild-type genotype was evaluated on Mean weekly warfarin dose. Patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes required lower mean weekly warfarin doses (28.21 mg and 24.47 mg) compared to those with the CYP2C9*1/*1 wild-type genotype (33.90 mg).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: